PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33603137-2	2021	The complex in vitro profile of buprenorphine, with affinity for micro-, delta-, and kappa-opioid receptors (OR), makes it difficult to predict its dose-related neuropharmacology in vivo.	Buprenorphine	32-45	opioid receptor kappa 1	Homo sapiens	65-107	
2823167-0	1987	Buprenorphine has potent kappa opioid receptor antagonist activity.	Buprenorphine	0-13	opioid receptor kappa 1	Homo sapiens	25-46	
16953647-3	2006	Buprenorphine has partial mu-opioid receptor agonist activity and is a kappa-opioid receptor antagonist; hence, it can substitute for other micro-opioid receptor agonists, yet is less apt to produce overdose reactions or dysphoria.	Buprenorphine	0-13	opioid receptor kappa 1	Homo sapiens	71-92	
32204739-8	2020	Additionally, KOR likely mediates the antidepressant and some of the anxiolytic effects of buprenorphine.	Buprenorphine	91-104	opioid receptor kappa 1	Homo sapiens	14-17	
32204739-12	2020	Further studies are necessary to study the involvement of endogenous opioid systems, and specifically KOR, in mediating buprenorphine"s beneficial effects and the ability to treat these medical conditions while minimizing risks for misuse and diversion.	Buprenorphine	120-133	opioid receptor kappa 1	Homo sapiens	102-105	
30553825-1	2019	Modulation of the opioid system has re-emerged as a potential therapeutic avenue for treating depression, with efficacy of a fixed-dose combination of buprenorphine (BUP), a partial mu-opioid receptor (MOR) agonist and kappa-opioid receptor (KOR) antagonist, and samidorphan (SAM), a potent MOR antagonist, as an adjuvant treatment in patients with major depressive disorder (MDD).	Buprenorphine	151-164	opioid receptor kappa 1	Homo sapiens	242-245	
25191915-1	2014	OBJECTIVE: To describe the clinical effect and safety of low-dose buprenorphine, a kappa-opioid receptor antagonist, for treatment-resistant depression (TRD) in midlife and older adults.	Buprenorphine	66-79	opioid receptor kappa 1	Homo sapiens	83-104	
19305793-6	2008	Buprenorphine is a partial micro-opioid receptor agonist and a kappa-opioid receptor antagonist.	Buprenorphine	0-13	opioid receptor kappa 1	Homo sapiens	63-84	
31994020-3	2020	Buprenorphine is considered a partial agonist with very high binding affinity for the mu-opioid receptor, an antagonist with high binding affinity for the delta- and kappa-opioid receptors, and an agonist with low binding affinity for the opioid receptor-like 1 receptor.	Buprenorphine	0-13	opioid receptor kappa 1	Homo sapiens	155-188	
30664299-3	2019	The aim of this study is to compare response of PTSD symptoms when antagonizing KOR via buprenorphine/naloxone compared to SSRIs or opioid therapy.	Buprenorphine	88-101	opioid receptor kappa 1	Homo sapiens	80-83	
24274990-8	2014	On one hand, the hypothesis that possible gene-related changes in kappa-opioid receptor could consistently affect buprenorphine pharmacological action and clinical effectiveness was not confirmed in our study, at least in relation to the single nucleotide polymorphism 36G>T. On the other hand, the possibility that gene-related dopamine changes could have reduced BUP effectiveness and impaired maintenance treatment outcome was cautiously supported by our findings.	Buprenorphine	114-127	opioid receptor kappa 1	Homo sapiens	66-87	
22119647-1	2012	Buprenorphine (BUP) is a partial agonist at mu-, delta- and ORL1 (opioid receptor-like)/nociceptin receptors and antagonist at the kappa-opioid receptor site.	Buprenorphine	0-13	opioid receptor kappa 1	Homo sapiens	131-152	
20420250-3	2010	At higher doses, buprenorphine potentiates antagonism at the kappa-opioid receptor.	Buprenorphine	17-30	opioid receptor kappa 1	Homo sapiens	61-82	
12481193-2	2002	Its actions at these receptors have not been completely characterized, although buprenorphine is generally regarded as a mu-opioid receptor partial agonist and a kappa-opioid receptor antagonist.	Buprenorphine	80-93	opioid receptor kappa 1	Homo sapiens	162-183	
34223499-3	2021	Buprenorphine is a partial mu receptor agonist and a kappa-opioid receptor antagonist, with a better safety profile than full mu receptor agonists.	Buprenorphine	0-13	opioid receptor kappa 1	Homo sapiens	53-74